Single-center, Open-label, Randomized, Two-period, Two-way Crossover Study to Investigate the Bioequivalence of a Single-dose of 12 mg IVERMECTIN Administered as Orally Disintegrating Mini Tablets (CHILD-IVITAB) Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets (STROMECTOL) in Healthy Adults Under Fasting Conditions
Latest Information Update: 23 Dec 2022
At a glance
- Drugs Ivermectin (Primary)
- Indications Helminthiasis; Onchocerciasis; Scabies
- Focus Pharmacokinetics
Most Recent Events
- 20 Dec 2022 Status changed from not yet recruiting to completed.
- 03 Aug 2022 New trial record